This echoes what MON said on its FY4Q11 CC last week (#msg-67723695).
Biotech seeds and traits comprise only 20% of SYT’s sales (compared to 73% for MON), but this is where a large portion of SYT’s growth is expected to come from.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.